NCT02346175View on ClinicalTrials.gov

Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

SHR3824

DRUG

Placebo

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02346175 - Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients | Biotech Hunter | Biotech Hunter